A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thi

Trial Details

NCT ID

NCT07293247

Phase

PHASE2

Sponsor

Alliance for Clinical Trials in Oncology

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Chemotherapy
Immunotherapy
Intensity-Modulated Radiation Therapy
Computed Tomography
Magnetic Resonance Imaging
Fludeoxyglucose F-18

Locations (sample)

Jonesboro, Arkansas, United States|35.8423,-90.70428
Los Angeles, California, United States|34.05223,-118.24368
Parker, Colorado, United States|39.5186,-104.76136
Aventura, Florida, United States|25.95648,-80.13921
Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

Histopathologic diagnosis of NSCLC, may have mixed or multiple histologies but no small cell component
No known EGFR mutation or ALK rearrangement
No metastatic disease (M0) per most recent PET/CT and head CT/MRI imaging
No disease progression per CT chest (including upper abdomen as per standard practice) with intravenous (IV) contrast (unless IV contrast is contra…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →